Product Description
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Denmark | Egypt | India | Ireland | Italy | Korea | New Zealand | Pakistan | Portugal | South Africa | Spain | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Osteomyelitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PRESTO:Osteo | P1 |
Terminated |
Osteomyelitis |
2018-11-07 |